Clinical Trial Update: Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration

View source ↗

Summary

This clinical trial update describes evaluating switching from 2 mg aflibercept to 8 mg aflibercept in patients with neovascular age-related macular degeneratio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Vienna Institute for Research in Ocular Surgery | Conditions: Neovascular (Wet) Age-Related Macular Degeneration | Status: ACTIVE_NOT_RECRUITING